www.klinickafarmakologie.cz / Klin Farmakol Farm. 2024;38(1):38-45 / KLINICKÁ FARMAKOLOGIE A FARMACIE 45 FARMAKOLOGICKÝ PROFIL Farmakologický profil mavakamtenu v léčbě hypertrofické obstrukční kardiomyopatie 19. Nistri S, Olivotto I, Maron MS, et al. β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012 Sep;110(5):715-719. 20. Anderson DM, Raff GL, Ports TA, et al. Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function. Br Heart J. 1984;51(5):523-529. 21. Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation. 1985;72(4):853-864. 22. Kimmelstiel C, Zisa DC, Kuttab JS, et al. Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. Circ Cardiovasc Interv. 2019;12(7):e007673. 23. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-3626. Zkrácenou informaci o přípravku naleznete zde: https://www.bms.com/assets/bms/cz/en/documents/ CAMZYOS_ZIP.pdf 3500-CZ-2400021
RkJQdWJsaXNoZXIy NDA4Mjc=